| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $24,375 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Culley Brian M | President and CEO | 1 | $24,375 | 0 | $0 | $24,375 |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It …
Over the last 12 months, insiders at Lineage Cell Therapeutics, Inc. have bought $24,375 and sold $0 worth of Lineage Cell Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Lineage Cell Therapeutics, Inc. have bought $3.33M and sold $1.32M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Culley Brian M (President and CEO) — $24,375.
The last purchase of 15,000 shares for transaction amount of $24,375 was made by Culley Brian M (President and CEO) on 2026‑03‑12.
| 2026-03-12 | Culley Brian M | President and CEO | 15,000 0.0067% | $1.63 | $24,375 | -24.05% | ||
| 2025-01-27 | BROADWOOD PARTNERS, L.P. | 7.89M 4.4378% | $0.76 | $6M | +65.85% | |||
| 2024-11-26 | Howe Jill Ann | Chief Financial Officer | 15,000 0.0082% | $0.59 | $8,850 | +14.87% | ||
| 2024-11-26 | Samuel George A. III | General Counsel | 15,000 0.0083% | $0.60 | $9,000 | +14.87% | ||
| 2024-11-22 | Mulroy Michael H. | director | 40,000 0.0237% | $0.57 | $22,640 | +36.83% | ||
| 2024-11-21 | Culley Brian M | President and CEO | 40,000 0.0213% | $0.60 | $24,000 | +14.63% | ||
| 2024-08-16 | Howe Jill Ann | Chief Financial Officer | 10,500 0.0059% | $0.89 | $9,345 | -20.63% | ||
| 2024-05-24 | Culley Brian M | President and CEO | 10,000 0.0054% | $1.05 | $10,500 | -31.53% | ||
| 2024-02-08 | BAILEY DON M | director | 96,155 0.0563% | $1.04 | $100,001 | -15.51% | ||
| 2024-02-06 | BROADWOOD PARTNERS, L.P. | 6.73M 3.9412% | $1.04 | $7M | -17.65% | |||
| 2023-12-29 | Jayasuriya Anula | director | 10,000 0.0057% | $1.09 | $10,900 | -11.37% | ||
| 2022-03-31 | Culley Brian M | President and CEO | 6,400 0.0037% | $1.53 | $9,792 | -11.04% | ||
| 2022-03-28 | Amin Dipti | 35,000 0.0227% | $1.63 | $57,050 | -7.43% | |||
| 2022-03-25 | Culley Brian M | President and CEO | 5,250 0.0029% | $1.38 | $7,245 | -7.43% | ||
| 2022-03-24 | Mulroy Michael H. | 7,000 0.004% | $1.40 | $9,800 | -4.86% | |||
| 2022-03-23 | BRADSHER NEAL C | 0 – | $0 | $0 | -0.72% | |||
| 2021-12-29 | Sale | Hogge Gary S. | SVP,Clinical & Medical Affairs | 37,695 0.0227% | $2.45 | $92,438 | -43.21% | |
| 2021-12-28 | Sale | Hogge Gary S. | SVP,Clinical & Medical Affairs | 501,588 0.298% | $2.45 | $1.23M | -43.70% | |
| 2021-06-29 | Sale | Russell Angus C. | director | 4,720 0.0029% | $2.97 | $14,018 | -29.69% | |
| 2021-06-29 | Sale | ANDREWS DEBORAH J | director | 19,142 0.0117% | $2.93 | $56,086 | -29.69% |
| Culley Brian M | President and CEO | 255516 0.101% | $258,071.16 | 6 | 1 | <0.0001% |
| BROADWOOD PARTNERS, L.P. | 49560992 19.5965% | $50.06M | 20 | 1 | +11.95% | |
| BRADSHER NEAL C | 34265485 13.5487% | $34.61M | 4 | 0 | <0.0001% | |
| KINGSLEY ALFRED D | See Remarks | 5781555 2.286% | $5.84M | 13 | 8 | |
| WEST MICHAEL D | Co-Chief Executive Officer | 882864 0.3491% | $891,692.64 | 3 | 1 | +1.12% |
| Peabody Robert | Sr. VP, COO, and CFO | 315777 0.1249% | $318,934.77 | 1 | 1 | +6.44% |
| Mulroy Michael H. | director | 298555 0.118% | $301,540.55 | 2 | 0 | +15.99% |
| BAILEY DON M | director | 158801 0.0628% | $160,389.01 | 1 | 0 | <0.0001% |
| Cartt Stephen LaHue | director | 155125 0.0613% | $156,676.25 | 3 | 0 | +6.94% |
| LICHTINGER PEDRO | director | 126250 0.0499% | $127,512.50 | 2 | 0 | <0.0001% |
| FARRELL STEPHEN C | director | 97450 0.0385% | $98,424.50 | 6 | 0 | <0.0001% |
| MOHANTY ADITYA P. | Co-Chief Executive Officer | 89696 0.0355% | $90,592.96 | 1 | 0 | <0.0001% |
| Russell Angus C. | director | 87500 0.0346% | $88,375.00 | 1 | 1 | <0.0001% |
| Amin Dipti | 35000 0.0138% | $35,350.00 | 1 | 0 | <0.0001% | |
| SCHLACHET DAVID | director | 32050 0.0127% | $32,370.50 | 1 | 0 | +11.75% |
| Howe Jill Ann | Chief Financial Officer | 25500 0.0101% | $25,755.00 | 2 | 0 | <0.0001% |
| Samuel George A. III | General Counsel | 22184 0.0088% | $22,405.84 | 1 | 0 | +14.87% |
| ANDREWS DEBORAH J | director | 15578 0.0062% | $15,733.78 | 5 | 1 | <0.0001% |
| BURNS ARNOLD I | director | 15000 0.0059% | $15,150.00 | 1 | 0 | <0.0001% |
| COHEN ABRAHAM E | director | 10000 0.004% | $10,100.00 | 1 | 0 | <0.0001% |
| Jayasuriya Anula | director | 10000 0.004% | $10,100.00 | 1 | 0 | <0.0001% |
| Patton Stephana Eilene | General Counsel | 7500 0.003% | $7,575.00 | 1 | 0 | <0.0001% |
| GARCIA PETER S | Chief Financial Officer | 7000 0.0028% | $7,070.00 | 2 | 0 | <0.0001% |
| Roberts Brandi | CFO & SVP, Finance | 5000 0.002% | $5,050.00 | 1 | 0 | <0.0001% |
| Leavitt Chase C. | General Counsel/Secretary | 5000 0.002% | $5,050.00 | 1 | 0 | <0.0001% |
| VON ESCHENBACH ANDREW C. | director | 3000 0.0012% | $3,030.00 | 1 | 0 | <0.0001% |
| SKIBSTED RUSSELL | Chief Financial Officer | 2000 0.0008% | $2,020.00 | 1 | 0 | <0.0001% |
| BERGER FRANKLIN M | director | 500 0.0002% | $505.00 | 1 | 0 | <0.0001% |
Lineage Cell Therapeutics, Inc. (LCTX) | $60,836,085 | 69 | 0.45% | $255.44M |
$19,239,249 | 50 | -2.24% | $238.33M | |
$109,019,806 | 28 | 7.37% | $263.86M | |
$3,668,031 | 23 | 2.05% | $243.03M | |
$295,092,700 | 21 | -0.27% | $237.78M |
| Increased Positions | 54 | +42.86% | 11M | +11.2% |
| Decreased Positions | 42 | -33.33% | 4M | -4.32% |
| New Positions | 24 | New | 3M | New |
| Sold Out Positions | 12 | Sold Out | 2M | Sold Out |
| Total Postitions | 138 | +9.52% | 102M | +6.88% |
| Broadwood Capital Inc | $81,280.00 | 21.55% | 49.56M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $14,771.00 | 3.92% | 9.01M | +524,057 | +6.18% | 2025-09-30 |
| Defender Capital, Llc. | $11,163.00 | 2.96% | 6.81M | +21,400 | +0.32% | 2025-09-30 |
| Raffles Associates Lp | $8,836.00 | 2.34% | 5.39M | -4,300 | -0.08% | 2025-09-30 |
| Comerica Bank | $7,544.00 | 2% | 4.6M | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $4,395.00 | 1.17% | 2.68M | +79,426 | +3.05% | 2025-09-30 |
| Geode Capital Management, Llc | $3,968.00 | 1.05% | 2.42M | -11,853 | -0.49% | 2025-09-30 |
| Blackrock, Inc. | $3,658.00 | 0.97% | 2.23M | -29,992 | -1.33% | 2025-09-30 |
| Renaissance Technologies Llc | $3,125.00 | 0.83% | 1.91M | -66,702 | -3.38% | 2025-09-30 |
| Dauntless Investment Group, Llc | $2,647.00 | 0.7% | 1.61M | +408,170 | +33.85% | 2025-09-30 |